Skip to contentA
Arcus Biosciences, Inc.
A
RCUSArcus Biosciences, Inc. Released Mar 5, 2019, after the close
10-K filed Mar 5, 2019, 64 days after period end · 0001564590-19-006274
Q4 2018 · 10-K
Revenue$1.56M$1.56M+25.0% vs Q4 2017−63.6% vs Q3 2018 Net Income-$12.30M-$12.30M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
N/M vs Q3 2018
Operating Incomederived-$13,484,000N/M Operating Cash Flowderived-$7,107,000N/M Free Cash Flowderived-$7,365,000N/M Margins · derivedOperating margin-863.3%+204.2 pt vs Q4 2017
Net margin-787.1%+269.7 pt vs Q4 2017
Filing lag
ended Dec 31, 2018 · filed Mar 5, 2019 · 64 d after period end
7.0% from the close of Mar 5, 2019 to the close of Mar 6, 2019, the first after the release.
after the close$12.02$11.18 Jan 14Mar 5Jun 4